Authors
Loading...
Randomized trial evaluates MRPL23 expression and its impact on survival in glioblastoma, suggesting its role as a biomarker.
Durślewicz et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: